Expert Review of Anticancer Therapy最新文献

Epidemiologic and survival analysis for patients with secondary esophageal Cancer: a population-based study and external validation. 继发性食管癌患者的流行病学和生存分析：一项基于人群的研究和外部验证。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-12 DOI: 10.1080/14737140.2025.2517883

Jie Wang, Jingyun Zha, Xiaoliang Dong, Ping Liu

{"title":"Epidemiologic and survival analysis for patients with secondary esophageal Cancer: a population-based study and external validation.","authors":"Jie Wang, Jingyun Zha, Xiaoliang Dong, Ping Liu","doi":"10.1080/14737140.2025.2517883","DOIUrl":"10.1080/14737140.2025.2517883","url":null,"abstract":"Background: There is a lack of dedicated studies addressing the epidemiology, prognostic factors, and optimal management strategies for secondary esophageal cancer (SEC).Methods: This study sourced data from the SEER database and an independent external cohort. Annual percentage change (APC) was calculated to qualify the incidence trend. Cox regression was employed for survival analysis.Results: A total of 13,792 sec cases from the SEER database and 63 cases from the validation cohort were included in this study. The incidence of SEC increased from 0.95 per 100,000 persons in 2000 to 1.2 per 100,000 in 2008, stabilizing thereafter. Survival analysis identified disease stage, age, and tumor location as significant prognostic factors (All p < .05). A prognostic model incorporating these variables demonstrated robust predictive accuracy across training, testing, and validation cohorts, with a C-index of around 0.73. In terms of treatment, radiotherapy and chemotherapy were associated with improved survival, while no significant benefit for younger patients and those with early-stage or squamous cell carcinoma.Conclusions: There remains a critical need for early detection methods and the implementation of more personalized treatment strategies. The developed prognostic model provides a framework for risk stratification, supporting the optimization of therapeutic decisions and improving patient outcomes.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"949-959"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The current landscape of neoadjuvant therapy for resectable colon cancer. 可切除结肠癌新辅助治疗的现状。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-10 DOI: 10.1080/14737140.2025.2517881

Mei Chan, Tharani Krishnan, Amanda Townsend, Christos Karapetis, Amitesh Roy, Tiffany Foo, Niall Tebbutt, Tony Dhillon, Timothy Price

{"title":"The current landscape of neoadjuvant therapy for resectable colon cancer.","authors":"Mei Chan, Tharani Krishnan, Amanda Townsend, Christos Karapetis, Amitesh Roy, Tiffany Foo, Niall Tebbutt, Tony Dhillon, Timothy Price","doi":"10.1080/14737140.2025.2517881","DOIUrl":"10.1080/14737140.2025.2517881","url":null,"abstract":"Introduction: Neoadjuvant therapy has been proposed as a safe and effective treatment option for resectable colon cancer, providing several advantages over the current standard adjuvant protocol.Areas covered: This review summarizes the recent developments in neoadjuvant strategies for resectable colon cancer, highlighting key clinical trial data, current and emerging challenges, and the role of precision medicine in guiding treatment. Sources for this review were obtained through searches of PubMed, ClinicalTrials.gov, and relevant conference abstracts.Expert opinion: Neoadjuvant therapy is emerging as a promising approach for treating colon cancer, especially for dMMR/MSI-H colon cancer where neoadjuvant immunotherapy have shown exceptional complete pathologic response rates and durable responses. Ongoing trials are focused on identifying optimal treatment approaches that balance oncological efficacy with the minimization of toxicity. A reliable multimodal evaluation framework incorporating advanced staging techniques and biomarkers such as circulating tumor DNA is essential to guide treatment and improve patient selection.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"901-913"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Maintenance therapy in patients with unresectable metastatic colorectal cancer receiving oxaliplatin plus antiangiogenic-based induction regimen: a study cohorts analysis. 不可切除的转移性结直肠癌患者接受奥沙利铂加基于抗血管生成诱导方案的维持治疗：一项研究队列分析

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 DOI: 10.1080/14737140.2025.2536107

Giuseppe A Colloca, Antonella Venturino

{"title":"Maintenance therapy in patients with unresectable metastatic colorectal cancer receiving oxaliplatin plus antiangiogenic-based induction regimen: a study cohorts analysis.","authors":"Giuseppe A Colloca, Antonella Venturino","doi":"10.1080/14737140.2025.2536107","DOIUrl":"10.1080/14737140.2025.2536107","url":null,"abstract":"Objectives: Maintenance therapy is frequently proposed to patients with unresectable metastatic colorectal cancer (mCRC). However, the optimal regimen has not been defined, and studies have failed to characterize the patients who benefit from the maintenance strategy.Research design and methods: A systematic search of studies of maintenance was performed. Prospective studies that evaluated the progression-free survival (PFS) from the start of induction to progression and reported overall survival (OS) were selected. The efficacy of induction + maintenance therapy was assessed by the PFS/OS ratio. Twenty-one baseline variables were extracted and a linear regression was performed, separating cohorts in which maintenance included antiangiogenic agent (AAG)-based or fluoropyrimidine (FP)-based regimen.Results: Twenty-three study cohorts related to 18 trials were selected. Analysis of variables versus PFS/OS ratio showed a significant relationship with sex (23 cohorts; β = -0.0082, p-value = 0.016). In the 19 cohorts that received an AAG-based regimen, a benefit was found for females, patients receiving longer oxaliplatin-based induction chemotherapy, lung metastases, while in the 17 cohorts that received an FP-based treatment only patients without a previous primary tumor resection reported higher PFS/OS.Conclusions: Despite the heterogeneity of the studies, female sex was associated with a more pronounced effect of maintenance regimens, particularly AAG-based.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on the therapeutic options for metastatic thymomas and thymic carcinomas. 转移性胸腺瘤和胸腺癌治疗选择的最新进展。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-16 DOI: 10.1080/14737140.2025.2519858

Yoshihiro Masui, Yusuke Okuma

{"title":"An update on the therapeutic options for metastatic thymomas and thymic carcinomas.","authors":"Yoshihiro Masui, Yusuke Okuma","doi":"10.1080/14737140.2025.2519858","DOIUrl":"10.1080/14737140.2025.2519858","url":null,"abstract":"Introduction: Thymic epithelial tumors are rare cancers originating from the thymus, with an annual incidence of 0.13 per 100,000 persons. Therefore, the standard of care was approved primarily based on the results of single-arm phase II trials. If the disease is resectable and localized, a multidisciplinary treatment combining surgical resection, radiotherapy, and pharmacotherapy should be considered. Pharmacotherapy is the mainstay of treatment for metastatic and recurrent diseases.Areas covered: This review delineates the distinct difference in treatment strategies of chemotherapy in patients with thymomas and thymic carcinomas. Thymomas typically respond to a cisplatin and anthracyclines, often supplemented with steroids, whereas thymic carcinomas, which do not typically involve anthracyclines as key drugs, are treated with platinum-based doublet chemotherapy. Lenvatinib has emerged as a pivotal key drug for refractory thymic carcinoma. In addition, single-agent cytotoxic chemotherapy, molecular targeted therapies, and immune checkpoint inhibitors is considered as key drugs for thymic carcinomas.Expert opinion: Current research is focused on developing novel therapeutics such as antibody-drug conjugates (ADCs), angiogenesis inhibitors, multi-kinase inhibitors, and further immune checkpoint inhibitors, expanding the prospects for pharmacotherapy in thymic malignancies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"853-863"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

RASGEF1C affects aerobic glycolysis and facilitates lung cancer progression through the PLK1 signaling pathway. RASGEF1C通过PLK1信号通路影响有氧糖酵解并促进肺癌进展。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-23 DOI: 10.1080/14737140.2025.2518278

Hao Wu, Kang Zheng, Fei Han

{"title":"RASGEF1C affects aerobic glycolysis and facilitates lung cancer progression through the PLK1 signaling pathway.","authors":"Hao Wu, Kang Zheng, Fei Han","doi":"10.1080/14737140.2025.2518278","DOIUrl":"10.1080/14737140.2025.2518278","url":null,"abstract":"Objective: RasGEF domain family member 1C (RASGEF1C), primarily acting in neurological disorders, remains largely enigmatic regarding its function in lung cancer (LC).Methods: Bioinformatics analysis assessed the differential expression and prognosis of RASGEF1C in LC and analyzed the enriched pathways. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blot (WB) analyses were employed to assess the expression of RASGEF1C and polo-like kinase 1 (PLK1). Biological functions were detected by cell counting kit-8 (CCK-8), flow cytometry, colony formation assay, cell scratch assay, and Transwell assay. Glycolysis-related proteins were detected by Western blot, and ATP levels, glucose content, lactate production, extracellular acidification rate, and oxygen consumption rate were measured to assess glycolysis flux changes in a mouse xenograft tumor model. Immunohistochemistry was applied to detect levels of RASGEF1C, PLK1, and Ki67. WB was employed to assess the expression of RASGEF1C, PLK1, pyruvate kinase M2 (PKM2), and hexokinase 2 (HK2).Results: The upregulation of RASGEF1C in LC reinforced the malignant progression of tumors (p < 0.01). RASGEF1C activation of the PLK1 pathway enhanced aerobic glycolysis, promoting proliferation, migration, and anti-apoptotic behaviors in LC cells.Conclusions: RASGEF1C affects aerobic glycolysis through the PLK1 signaling pathway, thereby acting as a pro-cancer factor driving LC progression.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"961-971"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer. sacituzumab govitecan治疗晚期/转移性非小细胞肺癌的评估

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-05 DOI: 10.1080/14737140.2025.2515989

Irfan Cicin, Berivan Karatekin, Esra Güzelaltuncekic, Ilker Kolbas

{"title":"Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer.","authors":"Irfan Cicin, Berivan Karatekin, Esra Güzelaltuncekic, Ilker Kolbas","doi":"10.1080/14737140.2025.2515989","DOIUrl":"10.1080/14737140.2025.2515989","url":null,"abstract":"Introduction: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Despite advancements in targeted therapies and immune checkpoint inhibitors, many patients with advanced NSCLC experience disease progression, necessitating novel therapeutic approaches like antibody-drug conjugate (ADC).Areas covered: Sacituzumab govitecan, a trophoblast cell surface antigen 2 (Trop-2) - directed ADC, has emerged as a potential treatment for advanced NSCLC This review evaluates its mechanism of action, clinical efficacy, safety profile, and potential in combination therapies, particularly in heavily pretreated patients. A literature search was conducted using PubMed with keywords 'sacituzumab govitecan' and 'lung cancer,' incorporating relevant studies, including the EVOKE-01 trial.Expert opinion: Sacituzumab govitecan offers a promising alternative for patients unresponsive to conventional treatments. While it demonstrates encouraging response rates and manageable toxicity, further research is needed to refine patient selection and optimize combination strategies. Ongoing trials, such as KEYNOTE-D46/EVOKE-3 May 2001define its role in first-line NSCLC treatment.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"845-852"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ablative radiotherapy for polymetastatic disease: a new kid on the block. 消融放疗治疗多转移性疾病：一个新的孩子在街区。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 DOI: 10.1080/14737140.2025.2542191

Federico Camilli, Andrea Lancia, Sheetal R Kashid, Jatin Bhatia, Ajay Gubbi Vijayakumar, Asha Latha Devalla, Lorenzo Falcinelli, Simonetta Saldi, Cynthia Aristei, Beatrice Detti, Gianluca Ingrosso

{"title":"Ablative radiotherapy for polymetastatic disease: a new kid on the block.","authors":"Federico Camilli, Andrea Lancia, Sheetal R Kashid, Jatin Bhatia, Ajay Gubbi Vijayakumar, Asha Latha Devalla, Lorenzo Falcinelli, Simonetta Saldi, Cynthia Aristei, Beatrice Detti, Gianluca Ingrosso","doi":"10.1080/14737140.2025.2542191","DOIUrl":"https://doi.org/10.1080/14737140.2025.2542191","url":null,"abstract":"Introduction: In polymetastatic cancer, radiotherapy (RT) serves as a palliative and symptom-directed approach. Based on modern RT, ablative irradiation has acquired a central role as a metastasis-directed therapy (MDT). MDT is under investigation as a treatment option in patients with widespread metastatic disease.Areas covered: We aimed to describe the emerging field of radiotherapy-based MDT in polymetastatic disease.Expert opinion: New innovative approaches in radiation oncology allow for the precise and safe delivery of ablative doses to multiple disease sites throughout the body in the same treatment session and the tracking of tumors in real time without interruptions during systemic therapy. This treatment strategy could work synergistically with systemic therapy in two ways: [a] ablating high-risk or symptomatic metastases in polymetastatic patients may prevent further disease spread and reduce the overall tumor burden, even while systemic therapy continues to manage micrometastatic disease elsewhere; [b] delivering high doses of radiation to the tumor site leads to microenvironment modifications, inducing immunogenic cell death, releasing tumor antigens, and enhancing immune surveillance and systemic therapy efficacy. Several clinical trials are ongoing to improve tailored treatment strategies in the polymetastatic setting, which is one of the goals of precision medicine.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CAR-T cell therapy in T-Cell lymphoblastic leukemia/lymphoma: where do we stand now? CAR-T细胞治疗t淋巴母细胞白血病/淋巴瘤：目前进展如何？

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-08 DOI: 10.1080/14737140.2025.2515981

Pedro Chorão, Pilar Lloret, Pau Montesinos, Manuel Guerreiro

{"title":"CAR-T cell therapy in T-Cell lymphoblastic leukemia/lymphoma: where do we stand now?","authors":"Pedro Chorão, Pilar Lloret, Pau Montesinos, Manuel Guerreiro","doi":"10.1080/14737140.2025.2515981","DOIUrl":"10.1080/14737140.2025.2515981","url":null,"abstract":"Introduction: CAR-T therapies for relapsed or refractory (r/r) T-cell lymphoblastic leukemia/lymphoma (T-LL/L) faces challenges, with most clinical studies conducted in small, dispersed cohorts and often reviewed alongside preclinical studies. This review focuses exclusively on clinical studies, evaluating CAR constructs, safety and efficacy.Methods: A systematic review was conducted of databases, clinical trial registries, and abstracts from conferences (June 2014 to June 2024). Preclinical studies and studies lacking clinical details were excluded. Data on patient demographics, CAR-T characteristics, response rates, survival, and adverse events were analyzed.Results: Eleven CAR-T constructs targeting CD7 and two targeting CD5 were identified. Complete remission (CR/CRi) rates ranged from 55% to 100%, exceeding 80% in most studies. Relapse, often in extramedullary sites, ranged from 7% to 66%. Cytokine release syndrome and neurotoxicity were generally manageable. GVHD incidence varied (none to 60%), primarily in allogeneic CAR-T recipients. Infections contributed to 6-38% of treatment-related mortality.Conclusions: CAR-T therapy achieves high response rates in r/r T-LL/L and may serve as a bridge to allogeneic transplantation. However, the short follow-up and the duration of responses remain concerns, and challenges endure, including GVHD, immune recovery and infection control. Standardized reporting is crucial to optimize therapy outcomes and safety in future trials.Registration: PROSPERO (CRD420251024662).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"939-948"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biologically synthesized metallic nanocarriers for efficient therapy of breast cancer. 生物合成金属纳米载体有效治疗乳腺癌。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-11 DOI: 10.1080/14737140.2025.2515977

Saili Jagdale, Rajkumar Samanta, Mahavir Narwade, Niladri Haldar, Rajesh Jadon, Virendra Gajbhiye, Kavita R Gajbhiye

{"title":"Biologically synthesized metallic nanocarriers for efficient therapy of breast cancer.","authors":"Saili Jagdale, Rajkumar Samanta, Mahavir Narwade, Niladri Haldar, Rajesh Jadon, Virendra Gajbhiye, Kavita R Gajbhiye","doi":"10.1080/14737140.2025.2515977","DOIUrl":"10.1080/14737140.2025.2515977","url":null,"abstract":"Introduction: Breast cancer is one of the most common cancers in women and has a high mortality rate. Current treatment methods, including radiation, chemotherapy, and surgery, have limitations such as surrounding tissue damage and nonspecific toxicity, reducing their effectiveness. As a result, new therapeutic platforms are needed to enhance breast cancer treatment.Areas covered: Nanoparticles, particularly metallic nanoparticles, have shown significant potential in overcoming the limitations of conventional treatments. These nanoparticles offer advantages such as high loading capacity, biocompatibility, adjustable size, and surface modification flexibility, making them ideal for drug delivery. This review focuses on the synthesis of metallic nanoparticles, emphasizing chemical and green synthesis methods. The green synthesis method has gained attention due to its eco-friendliness, biological safety, and cost-effectiveness. Research advancements in biosynthesized metallic nanoparticles for breast cancer therapy are discussed.Expert opinion: The use of bio-synthesized magnetic nanoparticles in the treatment of breast cancer shows promise for both cytotoxicity and targeted medication delivery. By increasing anti-tumor immune responses, their optical and magnetic qualities improve immunotherapy's efficacy. Furthermore, It have the potential to provide potent anticancer treatments and stimulate multidisciplinary research to address current obstacles in the treatment of breast cancer, opening up new therapeutic development pathways.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"865-882"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma. 皮下泛膜炎样t细胞淋巴瘤患者的临床特征和预后。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-07 DOI: 10.1080/14737140.2025.2517280

Yaobin Lin, Shenghong Shi, Jiahui Wu, Shan Liu

{"title":"Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma.","authors":"Yaobin Lin, Shenghong Shi, Jiahui Wu, Shan Liu","doi":"10.1080/14737140.2025.2517280","DOIUrl":"10.1080/14737140.2025.2517280","url":null,"abstract":"Background: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare and highly heterogeneous cytotoxic T-cell lymphoma with unknown epidemiology, clinical features, and prognosis.Methods: We retrospectively analyzed data on patients with SPTCL from the Surveillance, Epidemiology, and End Results database (2000-2021). Joinpoint plots of incidence were created. Independent prognostic factors for overall survival (OS) and lymphoma-specific survival (LSS) were analyzed using univariate Cox regression analysis. Kaplan - Meier analyses were performed to assess survival.Results: Among 258 included patients, we observed an increase in the overall incidence of SPTCL, particularly among individuals aged ≥ 50. The age at SPTCL onset exhibited a unimodal distribution, with peak incidence in the 60-69-year age group. Multivariate Cox regression analysis indicated that diagnoses made between 2000 and 2006, as well as age ≥ 50, were associated with reduced OS and LSS. We describe a case of primary maxillofacial SPTCL in a pediatric patient at our center.Conclusions: SPTCL has unique clinical and pathological characteristics and tends to occur in younger patients. Early identification and active treatment are beneficial for improving prognosis and survival.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"973-981"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0